Schilke Tobin (CIK 1678984) reported 8 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-03-04). Recent activity: Sell CRNX (6,713 shares), Buy CRNX (32,000 shares), Buy CRNX (52,000 shares), Sell RVNC (97,999 shares), Sell RVNC (103,555 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Financial Officer | Sell | 6,713 | $266,305 |
| 2026-02-25 | Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Financial Officer | Buy | 32,000 | $0 |
| 2025-03-11 | Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Financial Officer | Buy | 52,000 | $0 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | CFO | Sell | 97,999 | $357,696 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | CFO | Sell | 103,555 | $0 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | CFO | Buy | 20,883 | $0 |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) | CFO | Sell | 20,883 | $0 |
| 2025-02-05 | Revance Therapeutics, Inc. (RVNC) | CFO | Buy | 6,888 | $0 |
Source: SEC Form 4 filings · as of 2026-03-04